The function of bacterial HtrA is evolutionally conserved in mammalian HtrA2/Omi

Hea-Jong Chung1,3,4, Mohammad Abu Hena Mostofa Jamal1,2,4 & Seong-Tshool Hong1*

Although the malfunction of HtrA2/Omi leads to Parkinson’s disease (PD), the underlying mechanism has remained unknown. Here, we showed that HtrA2/Omi specifically removed oligomeric α-Syn but not monomeric α-Syn to protect oligomeric α-Syn-induced neurodegeneration. Experiments using mnd2 mice indicated that HtrA2/Omi degraded oligomeric α-Syn specifically without affecting monomers. Transgenic Drosophila melanogaster experiments of the co-expression α-Syn and HtrA2/Omi and expression of genes individually also confirmed that pan-neuronal expression of HtrA2/Omi completely rescued Parkinsonism in the α-Syn-induced PD Drosophila model by specifically removing oligomeric α-Syn. HtrA2/Omi maintained the health and integrity of the brain and extended the life span of transgenic flies. Because HtrA2/Omi specifically degraded oligomeric α-Syn, co-expression of HtrA2/Omi and α-Syn in Drosophila eye maintained a healthy retina, while the expression of α-Syn induced retinal degeneration. This work showed that the bacterial function of HtrA to degrade toxic misfolded proteins is evolutionally conserved in mammalian brains as HtrA2/Omi.

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, characterized by the progressive loss of dopaminergic neurons in the substantia nigra of the central nervous system1. The degeneration of the dopaminergic neurons of the substantia nigra results in clinical manifestations such as motor impairments, which involve resting tremor, bradykinesia, postural instability, gait difficulty and rigidity2. Although the degeneration of dopaminergic neurons directly leads to the clinical manifestations of PD, the pathogenic mechanism underlying the degeneration of dopaminergic neurons at the molecular level is still unclear. The most manifested pathophysiological feature of dopaminergic neurons of PD is an abnormal accumulation of oligomeric α-Syn in the form of Lewy bodies and Lewy neurites inside neurons, which represent the major hallmarks of PD3. α-Syn is a 140-a.a. presynaptic protein that plays an important role in maintaining a supply of synaptic vesicles in presynaptic terminals4. α-Syn performs its normal biological function in neurons if present as a monomer. However, the monomeric form of α-Syn is naturally prone to adopt a β-sheet conformation to form oligomeric aggregates5. The oligomeric α-Syn has very strong neurotoxicity such that the aggregation plays a causative role in dopaminergic neuronal degeneration6.

Since the accumulation of misfolded α-Syn is a key to the pathology of PD, the question of how misfolded α-Syn is degraded by neurons has been actively investigated. Investigations over the last decades have elucidated that the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) work in conjunction to degrade α-Syn7,8. However, neither UPS nor ALP are specific pathways for α-Syn degradation but rather are for general intracellular protein turn-over pathways9,10. More importantly, none of the pathways have shown selectivity toward oligomeric α-Syn, and thus almost all the wasted proteins in cells, including monomeric α-Syn, are degraded by the pathways. Therefore, the mechanisms for oligomeric α-Syn degradation pathway to relieve the toxicity of oligomeric α-Syn in neurons remain completely unknown.

One of the dilemmas in neurons concerns the lack of toxicity of native monomeric α-Syn; rather, it is essential for proper neuronal functions, while oligomeric α-Syn is very neurotoxic11. Because of monomeric α-Syn plays indispensable roles in neurons, the α-Syn knock-out mouse showed impaired spatial learning and working memory12. Considering that monomeric α-Syn has a naturally strong tendency to self-aggregate into neurotoxic...
oligomers, it would be reasonable to speculate that neurons have an unknown pathway that specifically recognizes oligomeric α-Syn only to degrade oligomeric α-Syn without affecting the monomeric form.

HtrA2/Omi is a homolog of the bacterial heat shock protein HtrA (also known as DegP), which protects bacteria at elevated temperatures by specifically recognizing denatured proteins to degrade those proteins. HtrA2/Omi is evolutionarily well-conserved with respect to amino acid sequence and its three-dimensional structure, suggesting that the mammalian version of HtrA/DegP could also play proteolytic roles to specifically recognize and degrade denatured proteins in mammals. In fact, the HtrA2/Omi knockout mouse and the loss-of-function HtrA2/Omi mutant have both demonstrated that HtrA2/Omi functions as a neuroprotective protein to prevent PD. Accordingly, mutations in HtrA2/Omi have been repeatedly found in patients suffering from PD. However, the molecular mechanism underlying the neuroprotective role of HtrA2/Omi in PD has remained unknown until now, although it is certain that HtrA2/Omi plays an essential role in preventing PD.

Because the main function of HtrA/DegP in bacteria is to recognize misfolded or aggregated proteins to specifically degrade those proteins, we speculated that HtrA2/Omi could play an important role in removing misfolded or aggregated proteins in mammals as it does in bacteria. Because all the in vivo and clinical data consistently indicate that HtrA2/Omi is linked to PD progression and oligomeric α-Syn is the main misfolded protein aggregate in neurons, we investigated the potential molecular mechanism of HtrA2/Omi in terms of whether it specifically inhibits the formation of misfolded α-Syn or degrades oligomeric α-Syn to prevent PD. All of our in vitro and in vivo experiments using transgenic Drosophila and mice showed that HtrA2/Omi specifically recognizes and degrades oligomeric α-Syn but not monomeric α-Syn, indicating that HtrA2/Omi prevents oligomeric α-Syn-induced neurotoxicity to protect neurons from neurodegeneration by removing specifically misfolded or aggregated proteins, i.e., oligomeric α-Syn, just like it does in bacteria.

Results
HtrA2/Omi specifically recognized and degraded oligomeric α-Syn. To confirm our speculation concerning whether the function of HtrA2/Omi in mammals is evolutionary conserved to protect neurons from oligomeric α-Syn-induced toxicity, we examined how human recombinant HtrA2/Omi (hOmi) produced in E. coli BL21 (DE3) pLysS-pET28a+ reacted with oligomizerized α-Syn. As shown in Fig. 1a, hOmi specifically removed oligomeric α-Syn at 37–41 °C without affecting monomeric α-Syn. These data raised both possibilities that HtrA2/Omi removed oligomeric α-Syn by degradation or a chaperone action on oligomeric α-Syn to re-establish its monomeric form. To investigate these two possibilities of hOmi on oligomeric α-Syn, we specifically isolated oligomeric α-Syn from oligomizerized α-Syn (Supplementary Fig. 1a) using a size exclusion column. hOmi treatment of the purified oligomeric α-Syn resulted in complete degradation, while hOmi treatment had no effect on monomeric α-Syn (Fig. 1b). We further confirmed the oligomer-specific degradation of α-Syn by hOmi using the oligomer-specific fluorescent dye thioloavin-T (ThT). Supplementary Fig. 2 shows that hOmi not only degraded oligomeric α-Syn specifically but also in a manner that was dose-dependent on its substrate, oligomeric α-Syn, indicating that hOmi precisely recognizes only oligomeric α-Syn. These results clearly indicated that hOmi specifically recognized and degraded oligomeric α-Syn without affecting monomeric α-Syn, a native form of α-Syn. In addition, because of the specific removal of oligomeric α-Syn by hOmi, co-treatment of oligomizerized α-Syn consisting of a mixture of oligomeric and monomeric α-Syn resulted in a significant increase in cell viability in response to hOmi in a dose-dependent manner (Supplementary Fig. 3).

HtrA2/Omi is an evolutionarily well-conserved serine protease, and its protease activity is inhibited by UCF-101. As expected, UCF-101 completely inhibited the oligomeric α-Syn-specific protease activity of hOmi (Fig. 1a,b). These results indicated that the nucleophilic attack reaction by serine in the active site of hOmi was responsible for the oligomer-specific degradation of α-Syn. After identifying the enzymatic characteristics, we further analyzed the enzymatic kinetics of oligomeric α-Syn hydrolysis by hOmi after labeling α-Syn with ThT. The Lineweaver-Burk plot on the reactions yielded a K_{m} value of 2.569 μM and V_{max} value of 2.223 nmol/min/mg protein for oligomeric α-Syn degradation. This experiment revealed the enzymatic activity of hOmi against oligomeric α-Syn (Fig. 1c).

Loss of HtrA2/Omi led to an accumulation of oligomeric α-Syn in mouse brain. The in vitro experiments examining the effects of HtrA2/Omi on oligomeric α-Syn raised questions regarding the in vivo role of HtrA2/Omi. Before investigating the in vivo functions of HtrA2/Omi, we tested whether hOmi could function as a general protease like other serine proteases, such as trypsin, or as a specific protease for particular substrates. Coincubation of hOmi with brain extracts from mnd2, HtrA2/Omi-null mutant, mice and wild type did not reveal any noticeable proteolytic degradation unlike protease K (Fig. 2a), which indicated that hOmi functioned as a very specific protease. Western blotting of the gel with a α-Syn-specific monoclonal antibody showed that the mnd2/mnd2 mouse accumulated a large quantity of oligomeric α-Syn, unlike the wild type littermate control (Fig. 2b). The accumulation of a large quantity of oligomeric α-Syn in mnd2 mice cast light on the pathogenic mechanism by which the mutation of HtrA2/Omi causes PD. Since oligomeric α-Syn directly causes PD, it is reasonable that the accumulation of a large quantity of oligomeric α-Syn in mnd2 mice induces PD. hOmi treatment of the total protein extract from mnd2 mice resulted in complete degradation of the accumulated oligomeric α-Syn without affecting the monomers (Fig. 2b). This result suggests that the loss of HtrA2/Omi, as in mnd2/mnd2 mice, causes PD by the loss of its ability to degrade oligomeric α-Syn.

If the proteolytic activity of HtrA2/Omi is required to prevent oligomeric α-Syn-induced neurotoxicity, the intracellular localization of HtrA2/Omi and α-Syn should be equivalent. The immunohistochemical confocal microscopy experiments examining the substantia nigra and striatum of 4-week-old mnd2/mnd2 mice and their age-matched wild-type littermates confirmed the co-localization of HtrA2/Omi and α-Syn in mouse brain tissue (Fig. 2c), indicating that the intracellular localization of HtrA2/Omi and α-Syn is equivalent. The immunocytochemical study showed that α-Syn and HtrA2/Omi were located in mitochondria (Fig. 2d) and ER (Fig. 2e).
Overall, the mnd2 mouse experiments suggested that the failure of HtrA2/Omi to remove neurotoxic oligomeric α-Syn in the ER and mitochondria led to ER stress and mitochondrial dysfunction in neurons through the accumulation of a large quantity of oligomeric α-Syn, the hallmark of PD pathogenesis. Although ER stress and mitochondrial dysfunction in neurons are the most evident pathological phenomena observed in PD,23,24 the mechanisms underlying ER stress and mitochondrial dysfunction in PD neurons have not been elucidated. This work clearly showed the pathological mechanism of ER stress and mitochondrial dysfunction in PD.

Pan-neuronal expression of hOmi rescued Parkinsonism in a PD Drosophila model. After observing the specific degradation of oligomeric α-Syn by hOmi in mnd2 mice, we created a transgenic hOmi Drosophila with w1118 Drosophila melanogaster by inserting the full-length hOmi gene under the control of the UAS promoter (UAS-hOmi), where the heat shock 70 promoter was used to drive the expression of transposase (Fig.3). The transgenic hOmi Drosophila line was heterozygous for the dominantly marked balancer chromosome carrying a dominant mutation, CyO, which causes curly wings for easy detection. From the results of the genotyping and protein expression levels of transgenic hOmi Drosophila flies, Tg4 (x/y; hOmi/Cyo; +/+), in which UAS-hOmi was integrated into chromosome 2, was identified as the best hOmi transgenic line for subsequent experiments (Supplementary Fig. 4).

The hOmi Drosophila Tg4 was bred with a Drosophila model of PD (α-Syn Drosophila) carrying the homozygous human α-Syn gene (UAS-α-Syn) on chromosome 3 (Supplementary Fig. 5). Female α-Syn Drosophila were mated with male hOmi Drosophila, and +/+hOmi; α-Syn/+ flies were selected based on the dominant phenotypes of the CyO mutation. The F1 generation, +/+hOmi; α-Syn/+ flies, were crossed to generate various genotypes. The final homozygous x/y; hOmi/hOmi; α-Syn/α-Syn flies were selected after genotyping the progenies from the F2 generation. The male hOmi/hOmi; α-Syn/α-Syn flies were crossed with virgin female elav-GAL4 flies for pan-neuronal co-expression of hOmi and α-Syn (hOmi/α-Syn Drosophila, x/y; +/+hOmi; +/+α-Syn).

Figure 1. In vitro experiment showing that hOmi recognized and degraded specifically oligomeric α-Syn. (a) Removal of α-Syn oligomers (10 µg/mL) by hOmi (10 µg/mL) during the oligomerization of α-Syn at different temperatures. Treatment of UCF-101 (1 mM), a hOmi inhibitor, completely inhibited the oligomeric α-Syn-specific removal activity of hOmi. (b) Complete degradation of oligomeric α-Syn (10 µg/mL) without affecting monomeric α-Syn (10 µg/mL) by hOmi (10 µg/mL) at different temperatures but not in the presence of UCF-101 (1 mM). Treatment of UCF-101 (1 mM), a hOmi inhibitor, completely inhibited the oligomeric α-Syn-specific degradation activity of hOmi. (c) The Michaelis-Menten saturation curve (upper panel) and Lineweaver–Burk plot (lower panel) of hOmi for oligomeric α-Syn. The enzyme kinetic study was conducted after labeling oligomerized α-Syn with the oligomer-specific fluorescent dye ThT.
**Figure 2.** HtrA2/Omi specifically recognized and degraded oligomeric α-Syn in mouse brain. (a) hOmi (10 μg/mL) treatment on the total protein extracts of nigrostriatal tissues of wild-type, mnd2/+ and mnd2/mnd2 mice did not show any noticeable degradation by SDS-PAGE comparing the digestion with proteinase K (10 μg/mL). (b) Western blotting analysis on the total protein extracts with mouse anti-human α-Syn (4D6) revealed a significant accumulation of oligomeric α-Syn in the nigrostriatal tissues of mnd2/mnd2 mice and complete degradation of α-Syn oligomers after hOmi treatment, without affecting monomer. (c) Immunohistochemical confocal microscopy on the nigrostriatal tissue of wild-type, mnd2/+ and mnd2/mnd2 mice revealed the co-localization of α-Syn (green) and HtrA2/Omi (red), with significantly higher levels of α-Syn accumulation in mnd2/mnd2 mice. Representative images are shown along with the image analysis graph. (d) Immunostaining microscopy on the neurons in the substantia nigra and striatum showed co-localization of α-Syn (green), HtrA2/Omi (green) and mitochondria (red with Mito Tracker). Scale bar, 10 μM. (e) Immunostaining microscopy on neurons in the substantia nigra and striatum showed co-localization of α-Syn (green), HtrA2/Omi (green) and endoplasmic reticulum (red with ER marker PDI). Scale bar, 10 μM.
Since the Parkinsonism phenotype of α-Syn Drosophila is characterized by locomotor defects accompanied by reduced survivability, locomotor defects and survivability were tested in the hOmi, α-Syn and hOm-i/α-Syn Drosophila lines to assess the effect of hOmi on α-Syn-induced Parkinsonism (Fig. 4). As shown in Fig. 4a, loss of climbing ability of α-Syn Drosophila was completely rescued by co-expression with hOmi. The performance index of locomotion was significantly lower in α-Syn Drosophila than hOmi/α-Syn or hOmi Drosophila of the same age. As previously reported, the survival rate of α-Syn Drosophila was significantly reduced as a phenotype of Drosophila Parkinsonism. However, the survival rate of hOmi/α-Syn Drosophila was increased as much as wild type, indicating that HtrA2/Omi completely rescued the Drosophila Parkinsonism induced by α-Syn (Fig. 4b). Kaplan–Meier Survival analyses also showed that HtrA2/Omi completely rescued the Drosophila Parkinsonism (Supplementary Fig. 6). Overall, pan-neuronal co-expression of hOmi with α-Syn completely rescued the Parkinsonism phenotypes of α-Syn Drosophila. Additionally, it is interesting to note that pan-neuronal sole expression of hOmi (hOmi Drosophila) resulted in better performance in the locomotor reaction and increased survival rate compared with the wild type control.

Human HtrA2/Omi rescued the α-Syn-induced neurotoxicity in a PD Drosophila model by oligomeric α-Syn-specific degradation. To investigate how HtrA2/Omi rescues α-Syn-induced neurotoxicity in Drosophila, histological examinations were performed using the hOmi/α-Syn Drosophila line along with wild-type, hOmi and α-Syn Drosophila lines. Immunohistochemical confocal microscopy using an oligomer-specific monoclonal antibody, anti-α-Syn (ASY05), on brain sections showed that co-expression of hOmi and α-Syn completely eliminated the oligomeric α-Syn (Fig. 3a,b), which is consistent with the in vitro and mouse experiments (Figs. 1 and 2). Quantification of the green fluorescent intensity in the flies definitively
revealed a large quantity of oligomeric α-Syn accumulation only in α-Syn Drosophila (Fig. 3c). However, there were no detectable α-Syn oligomers in hOmi/α-Syn Drosophila. We further confirmed the specific degradation of α-Syn oligomers by hOmi with total protein extracts of hOmi/α-Syn fly brains (Fig. 3d). Anti-α-Syn antibody detected both oligomeric and monomeric α-Syn in α-Syn Drosophila. However, only monomeric α-Syn was detected by western blotting of hOmi/α-Syn Drosophila. This in vivo result clearly confirmed that HtrA2/Omi specifically recognized and degraded oligomeric α-Syn without affecting monomeric α-Syn. Considering that oligomeric α-Syn has strong neurotoxicity to function as an etiological agent for PD while monomeric α-Syn lacks neurotoxicity, rather playing an essential role in maintaining a supply of synaptic vesicles in presynaptic terminals27,28, this result shed light on how hOmi provides a neuroprotective function in PD.

We further investigated Drosophila brains after immunostaining with anti-α-Syn and anti-HtrA2/Omi antibodies. An age-dependent accumulation of α-Syn clearly caused the accumulation of Lewy bodies in α-Syn Drosophila (Fig. 5a,b). The integrity of the brain tissue was observed in both young and aged hOmi/Drosophila as in the case of control flies and hOmi Drosophila, but not in aged α-Syn Drosophila due to neurodegeneration. The brains of 40-day-old α-Syn Drosophila showed a clear neuronal loss with astrocytosis and the appearance of Lewy bodies both in male (Fig. 5a) and female flies (Fig. 5b). In accordance with the previous results concerning the function of hOmi in oligomeric α-Syn-specific degradation, this result again confirmed that hOmi rescued the α-Syn-induced neurotoxicity in α-Syn Drosophila.

Human HtrA2/Omi counteracted the α-Syn-induced developmental defect in Drosophila eye. It has been previously observed that the expression of α-Syn in the developing eye causes retinal degeneration in Drosophila29. Since α-Syn-induced retinal degeneration well-represented α-Syn-induced neurotoxicity, we
Figure 5. HtrA2/Omi prevented the formation of Lewy bodies and maintained brain integrity in a PD Drosophila model. (a) Immunohistochemical staining images on the midbrains of the transgenic flies expressing hOmi, α-Syn or hOmi/α-Syn with either anti-α-Syn or anti-hOmi antibody showed Lewy bodies (indicated as arrows) at 10 and 40-day-old male flies (n = 30). (b) Immunohistochemical staining images on the midbrains of the transgenic flies expressing hOmi, α-Syn or hOmi/α-Syn with either anti-α-Syn or anti-hOmi antibody showed Lewy bodies (indicated as arrows) at 10 and 40-day-old female flies (n = 30). The hOmi was stained with anti-hOmi (AA0134–458) followed by horse anti-mouse IgG (H + L) secondary antibody. The α-Syn was stained with an oligomeric α-Syn-specific monoclonal antibody, anti-α-Syn (ASy05), followed by horse anti-mouse IgG (H + L) secondary antibody. Scale bar, 50 µM.
functions as a neuroprotective protein to prevent PD. The presence of mutations/polymorphisms in HtrA2/Omi knock-out mouse and the natural HtrA2/Omi loss-of-function mutant mouse demonstrated that HtrA2/Omi is essential for maintaining the health of the brain. Although HtrA2/Omi specifically degraded only the neurotoxic form of α-Syn, oligomeric α-Syn, indicating that they are not these degradation pathways also degrade non-amyloidogenic monomeric α-Syn. Complete rescue of oligomeric α-Syn induction in vivo sheds light on the etiology of PD. Since PINK1 certainly phosphorylates HtrA2/Omi, there is a possibility that PINK1 may be involved in the regulation of HtrA2/Omi, although HtrA2/Omi does not function in the PINK1/Parkin pathway.

Thus far, thirteen genes that cause PD have been identified. The etiopathogenic mechanism of PD involving these genes can be grouped into two pathways: disruption of PINK1-associated phosphorylation in mitochondria and neurotoxic protein aggregation associated with α-Syn. Because both in vitro and genetic studies have suggested that HtrA2/Omi functions downstream of PINK1, our results could provide a key piece of the PD puzzle that links these two pathways at the molecular level.

The results of this study provide new findings about the neuroprotective role of HtrA2/Omi based on its ability to detoxify neurotoxic oligomeric α-Syn in PD. α-Syn is degraded by autophagy and the proteasome; however, in vivo and clinical observations showing an association of HtrA2/Omi with PD, HtrA2/Omi was named PARK13 to represent a PD gene.

Discussion
HtrA2/Omi is a mitochondrial protein with high homology to a bacterial heat shock protein. Therefore, it was speculated that HtrA2/Omi would function similarly to the bacterial protein to self-defense from stress-induced toxicity caused by cytotoxic drugs. Despite its protective role in bacteria, in vitro studies have shown that HtrA2/Omi acts as a pro-apoptotic protein. HtrA2/Omi is released into the cytosol from mitochondria during apoptosis and degrades inhibitor of apoptosis proteins (IAPs) such as XIAP and CIAP1/2. The degradation of these IAPs by HtrA2/Omi activates both caspase-dependent and -independent apoptotic pathways. Considering the pro-apoptotic characteristics of HtrA2/Omi, it would be normal to think that HtrA2/Omi could participate in a disease-escalating process rather than a disease-protecting process. However, in vivo animal experiments from both mice and insects have shown that HtrA2/Omi does not play a pro-apoptotic role, in contrast to the in vitro findings. Rather, HtrA2/Omi is not only dispensable for apoptosis but also allows brains to be maintained in a healthy state. This work showed the same basic trend as the previous results of in vivo HtrA2/Omi expression experiments. As shown in Figs. 4–5, expression of HtrA2/Omi in the Drosophila brain not only maintained the health and integrity of the brain but also increased life span. Thus, HtrA2/Omi showed demonstrated that the functions of HtrA2/Omi are essential for maintaining the health of the brain. Although apoptosis is the end of life to cells, some apoptosis is required to maintain the healthy state of multicellular organisms. In this context, the paradoxical results obtained for HtrA2/Omi in vitro and in vivo provide an abstruse example of the life process of multicellular organisms.

In accordance with pan-neuronal expression experiments of HtrA2/Omi in vivo, both of the HtrA2/Omi knock-out mouse and the natural HtrA2/Omi loss-of-function mutant mouse demonstrated that HtrA2/Omi functions as a neuroprotective protein to prevent PD. The presence of mutations/polymorphisms in HtrA2/Omi in sporadic PD patients further solidified the link of HtrA2/Omi to PD. Due to the functional loss of HtrA2/Omi in vivo and clinical observations showing an association of HtrA2/Omi with PD, HtrA2/Omi was named PARK13 to represent a PD gene.

Because mammalian HtrA2/Omi binds to PINK1 and the phosphorylation of HtrA2/Omi is dependent on PINK1, it has been suggested that HtrA2/Omi functions downstream of the PINK1/Parkin pathway. However, extensive loss-of-function-based genetic interaction studies using Drosophila have failed to show an association of HtrA2/Omi either upstream or downstream of PINK1. Gene interaction studies using mouse have also shown that overexpression of Parkin does not rescue neurodegeneration in the HtrA2/Omi mutant. These studies clearly indicate that HtrA2/Omi does not function in the PINK1/Parkin pathway. Although HtrA2/Omi certainly plays a neuroprotective role to prevent PD, the functional mechanism of HtrA2/Omi has remained mysterious until now. The gene interaction studies in this work clearly showed that HtrA2/Omi specifically degraded only the neurotoxic form of α-Syn, oligomeric α-Syn, without affecting non-toxic normal α-Syn (monomeric α-Syn). Complete rescue of oligomeric α-Syn-induced toxicity in vivo sheds light on the etiology of PD. Since PINK1 certainly phosphorylates HtrA2/Omi, there is a possibility that PINK1 may be involved in the regulation of HtrA2/Omi, although HtrA2/Omi does not function in the PINK1/Parkin pathway.

Thus far, thirteen genes that cause PD have been identified. The etiopathogenic mechanism of PD involving these genes can be grouped into two pathways: disruption of PINK1-associated phosphorylation in mitochondria and neurotoxic protein aggregation associated with α-Syn. Because both in vitro and genetic studies have suggested that HtrA2/Omi functions downstream of PINK1, our results could provide a key piece of the PD puzzle that links these two pathways at the molecular level. The results of this study provide new findings about the neuroprotective role of HtrA2/Omi based on its ability to detoxify neurotoxic oligomeric α-Syn in PD. α-Syn is degraded by autophagy and the proteasome; however, these degradation pathways also degrade non-amyloidogenic monomeric α-Syn, indicating that they are not related to the etiopathogenesis of PD. The oligomeric form of α-Syn is known to be resistant to all proteases, including proteinase K, and the clearance mechanism for amyloidogenic α-Syn has remained unknown. Our results show that oligomeric α-Syn is specifically degraded in neurons by HtrA2/Omi to prevent PD. HtrA2/Omi not only plays a critical role in the prevention of PD, but our results are also in good agreement with the previous
observation that HtrA2/Omi functions as a chaperone to detoxify oligomeric A\(\beta\) into monomeric A\(\beta\). Thus, HtrA2/Omi might be a key protein that relieves the stress caused by various amyloidogenic neuronal proteins such as oligomeric \(\alpha\)-Syn and oligomeric A\(\beta\).

Figure 6. HtrA2/Omi counteracted the \(\alpha\)-Syn-induced developmental defects in *Drosophila* eyes. (a, b) The H&E staining images of retinal sections of the transgenic flies expressing hOmi, \(\alpha\)-Syn, or hOmi/\(\alpha\)-Syn, at 10 and 40-day-old male a and female flies b (n = 30). Scale bar, 50 \(\mu\)M. (c, d) The light microscopic images of the eyes of the transgenic flies expressing hOmi, \(\alpha\)-Syn, or hOmi/\(\alpha\)-Syn at 10 and 40-day-old male c and female flies d (n = 30). Scale bar, 100 \(\mu\)M. (e, f) The scanning electron microscopic images of the eyes of the transgenic flies expressing hOmi, \(\alpha\)-Syn, or hOmi/\(\alpha\)-Syn at 10 and 40-day-old male e and female flies f (n = 30). Scale bar, 50 \(\mu\)M. The \(4 \times\) magnifications are presented in the square box. (g, h) Roughness counting of eye phenotypes based on normal phenotypes, loss of bristles and ommatidial disarray of the transgenic flies expressing hOmi, \(\alpha\)-Syn, or hOmi/\(\alpha\)-Syn at 10 and 40-day-old male g and female flies h (n = 30). Values are the mean ± SEM from three independent experiments. NS, not significant, \(^* p < 0.05, \quad ^{**} p < 0.001.\)
Amyloidalogenic proteins in mammalian brains such as Aβ, α-Syn and Prion share common biophysical and biochemical properties each other. These proteins are prone to adopt misfolded and aggregated conformation as oligomeric forms to cause neurodegenerations: Aβ in the case of Alzheimer's disease, α-Syn in the case of Parkinson's disease and prion in the case of Creutzfeldt-Jakob disease. In this regard, it would be very interesting to investigate the role of HtrA2/Omi on aggregated or oligomerized Aβ, α-Syn and Prion. In addition, these proteins are known to be present as different forms of oligomers with different levels of cytotoxicity. However, the etiological form of oligomers for neurodegeneration has not identified yet despite extensive efforts. Based on the neuroprotective function of HtrA2/Omi by degrading oligomeric α-Syn in vivo and the stained characteristic of in vitro oligomeric α-Syn with ThT, it seems to be that HtrA2/Omi degrades the toxic oligomeric form of oligomers etiologically responsible for PD.

It is well-known that the functions of most proteins are evolutionarily conserved. Bacteria have HtrA that specifically degrades misfolded proteins through its protease activity. The bacterial homolog of HtrA, HtrA2/Omi, functions as a protease to specifically degrade a type of misfolded protein, i.e., oligomeric α-Syn. Considering that the original function of HtrA was to degrade misfolded protein through its protease activity, it is very interesting to note that the function of the mammalian version of HtrA, HtrA2/Omi, is evolutionarily conserved to degrade misfolded protein, i.e., oligomeric α-Syn. Because oligomeric α-Syn is a typical example of misfolded proteins, the original function of HtrA seems to be perfectly conserved in mammalian brains.

**Methods and Materials**

**Reagents and antibodies.** The reagents used in all experiments and antibodies used for western blot or immunohistochemical analysis are listed in the Supplementary Table 1.

**Recombinant hOmi protein expression and purification.** The plasmid construct encoding hOmi (134–458) was generated using the pET28a+ vector (Novagen Merck Millipore). E. coli BL21 (DE3) pLysS (Stratagene California) was transfected with the recombinant vector construct by electroporation. A single colony of E. coli BL21 (DE3) pLysS-pET28a+HtrA2/Omi was grown at 37 °C/250 rpm in 1 L LB medium containing 50 µg/mL kanamycin until the OD reached ~ 0.8. One milliliter of IPTG was added to the culture, followed by further culture for 5 h at 20 °C/250 rpm to induce protein expression. After induction of heterologous protein, the bacterial cells were centrifuged at 6,000 × g for 15 min and stored at either −20 °C or at −80 °C until further use. The harvested bacterial pellet from the 1-L culture was washed once with PBS and resuspended in 20 mL of native cell lysis buffer A (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2.5 mM EDTA, 0.5% Triton X-100, 4 mM MgCl2, 50 µg/mL DNase I, 0.5 mg/mL lysozyme and protease inhibitor cocktail (Roche Applied Science)). After incubation at room temperature for 30 min, the lysate was subjected to sonication 10 times for 10 sec with a burst speed of 6 at high intensity with a 1 min cooling period on ice. Thereafter, the bacterial cell lysate was centrifuged at 20,000 × g for 1 h at 4 °C, and the supernatant was allowed to solubilize at room temperature overnight with constant stirring on a magnetic stirrer. The solubilized protein solution was centrifuged at 20,000 × g for 1 h to remove the insoluble materials, followed by an incubation at 4 °C for 1 h with gentle agitation to bind to a 5-mL Ni-NTA agarose affinity column (Invitrogen) pre-equilibrated with 30 mL of protein denaturing buffer C (50 mM Tris-HCl, pH 8.0, 5 mM urea, 500 mM NaCl and 20 mM imidazole) containing 10 mM imidazole. After binding, the column was washed sequentially with 30 mL and 75 mL of buffer C containing 10 mM and 50 mM imidazole, respectively. The denatured protein was then eluted with three column volumes of buffer C containing 500 mM imidazole. The Ni-NTA fractions were re-purified on a PD-10 column (Amersham Pharmacia Biotech) equilibrated with buffer C, followed by elution with the same buffer according to the manufacturer's instructions. After determining the purity of the purified protein, oligomerized α-Syn was checked by western blot using the same buffer according to the manufacturer's instructions.

**In vitro enzymatic assay of HrA2/Omi.** Commercially purchased human recombinant α-Syn protein (r-Peptide) was used in this work. For the preparation of oligomeric α-Syn, human recombinant monomeric α-Syn was diluted in Np buffer, pH 7.4, to a final concentration of 10 µg/mL and incubated at 37 °C. Ten microliters of recombinant hOmi (10 µg/mL in 50 mM sodium phosphate buffer, pH 7.4) produced in E. coli BL21 (DE3) pLysS-pET28a+ was incubated for 30 min at room temperature prior to addition of the same volume of human recombinant α-Syn protein (10 µg/mL). The reaction mixture was incubated at 37 °C, 39 °C and 41 °C each, UCF-101 (Merck Millipore), a HrA2/Omi specific inhibitor, was added to the reaction mixtures if necessary. To study oligomer-specific activity of HrA2/Omi, oligomeric and monomeric α-Syn were purified from in vitro oligomerized α-Syn using a PD-10 column using Sephadex® G-25M resin (Sigma Aldrich) according to the manufacturer's suggestions. Briefly, the dry powder of Sephadex was swollen in water overnight prior to use at 4 °C. An 1 mL micropipette tip was used for bedding, and the opening of the pipette was plugged with glass wool (Sigma Aldrich). The column was gently poured down the side of the pipette tip. The protein was eluted with sodium phosphate buffer. The purity of the purified monomeric and oligomeric α-Syn was checked by western...
blotting using a mouse anti-α-Syn antibody (1:200, Abcam). Thereafter, following the same procedure, an equal volume of purified α-Syn oligomer or monomer, 10 μg/mL, was incubated with the recombinant hOmi. The reaction mixtures were analyzed by western blotting using a mouse anti-α-Syn antibody.

**SDS-PAGE and western blotting.** The protein samples were mixed with NuPAGE 4 × LDS sample buffer (Invitrogen), heated at 95 °C for 5 min and run on a 4–12% Bis-Tris gradient gel (Invitrogen). The proteins were visualized by staining with Coomassie blue. For western blotting, the SDA-PAGE gels were transferred to PVDF membranes (Thermo Fisher Scientific). After blotting, the PVDF membranes were blocked with 5% non-fat dry milk (Bio-Rad Laboratories) in TBST (TBS with 0.05% Tween and 0.1% Triton X-100) for 2 h at room temperature. The membranes were washed with TBST and incubated overnight at 4 °C after adding mouse anti-α-Syn (1:2000, Abcam) or mouse anti-HtrA2/Omi antibody (1:2000, Antibodies-online GmbH). The membranes hybridized to the primary antibody were washed with TBST, followed by incubation for 2 h at room temperature after addition of a horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) antibody (1:3000, Promega Corporation). After washing with TBST, the chemiluminescent substrate, Immun-StarTM Western CTM Kit (Bio-Rad Laboratories, California, USA), was added to the membranes, and images were captured with an XRS camera equipped with a Bio-Rad Quantity One imaging system. The stock solutions of primary (anti-α-Syn and anti-HtrA2/Omi) and secondary antibodies (goat anti-mouse) were diluted with antibody dilution buffer (TBST-Triton X-100 with 0.5% BSA).

**Enzymatic kinetics of HtrA2/Omi using ThT.** To study the enzymatic kinetics of hOmi, 5 μM of oligomeric α-Syn was incubated with different concentration of hOmi (0 nM, 10 nM, 50 nM, and 100 nM) in 150 μL of 10 μM ThT (Sigma Aldrich) solution at room temperature using sealed 96-well plates. The ThT fluorescence intensity of each sample was measured at 485–540 nm every 5 min using an iMarkTM microplate reader (Bio-Rad Laboratories). The ThT fluorescence was also measured to obtain the Lineweaver-Burk plot. The plot of the reactions was used to calculate K_m and V_max values for hOmi.

**Mouse model.** This mouse study was carried out in strict accordance with the recommendations of the Guide for the Ethics Committee of Chonbuk National University Laboratory Animal Center. The protocol was approved by the Ethics Committee of Chonbuk National University Laboratory Animal Center (Permit Number: CBU 2012–0040) with the 'Guide for the Care and Use of Laboratory Animals', published by the National Research Council and endorsed by the ARRIVE Guidelines. All efforts were made to minimize suffering. The C57BL/6J-mnd2 mice (RRID: IMSR_JAX:004608) carrying a mutation at S276C in HtrA2/Omi, a Parkinson model mouse, were obtained from the Jackson Laboratory (Bar Harbor). Homozygous (mnd2/mnd2), heterozygous (mnd2/+), and wild-type mice were obtained by crossing mnd2 heterozygous (mnd2/+) mice. The genotypes of the mice were identified by PCR. All mice were maintained under a 12 h light/12 h dark cycle at 24 °C with 55% humidity with food and water ad libitum.

**Isolation of primary neurons from the substantia nigra and striatum.** The substantia nigra and striatum were obtained surgically from four-week-old wild-type C57BL/6 mice to investigate the localization of α-Syn and HtrA2/Omi. The substantia nigra and striatum were minced into small pieces in dissection medium (DMEM/F-12, 32 mM glucose, 1% penicillin/streptomycin, and 0.5 mM L-glutamine), followed by the addition of 2 mL of HBSS and centrifugation at 300 × g for 5 min. The pellet was treated with 2 mg/mL papain in HBSS and 200 μg/mL DNase I solution for 30 min in a 30 °C water bath with a platform rotating at 150 rpm. The tissue was gently triturated by the addition of dissection medium to the single cell suspension and passed through a cell strainer (BD Falcon). The neuronal pellets were washed twice with ice-cold dissection medium by centrifugation at 300 × g for 7 min and resuspended in pre-warmed Neurobasal/B27 growth medium supplemented with 1% penicillin/streptomycin, 0.5 mM L-glutamine, 10 ng/mL FGF2 (Sigma Aldrich), and 12.5 mM NaCl. The cells were seeded at a density of 120 cells/cm² on poly-D-lysine and laminin-coated multwell chambered cover slips (Grace Bio-Labs) and incubated in a humidified incubator at 37 °C in an atmosphere of 5% CO₂ and 95% air for 1 h for neuronal attachment. After 1 h, the spent medium was aspirated, followed by the addition of fresh growth medium for further incubation. Half of the spent medium was replaced every 3 days with the same volume of fresh pre-warmed growth medium containing 20 ng/mL FGF2.

**Cell viability assay.** The cell viability was evaluated using the Cell Counting Kit-8 (Sigma Aldrich). Primary mouse neurons were harvested, and 2 × 10^5 neurons were plated in 24-well polystyrene plates. The plates were incubated at 37 °C for 24 h for neuronal attachment. After 24 h, primary mouse neurons were treated with α-Syn and hOmi. The plates were then incubated at 37 °C for 48 h. After incubation, 10 μL of the reaction solution was added to each well and incubated for 4 h at 37 °C according to the manufacturer’s instructions. The absorbance of each well was then measured at 450 nm using a microplate reader (Bio-Rad Laboratories). All experiments were repeated at least three times.

**Preparation of protein extracts from the substantia nigra and striatum.** Four-week-old mnd2/ mnd2, mnd2/+ and age-matched control mice were sacrificed to isolate the substantia nigra and striatum surgically. Total proteins were extracted from the substantia nigra and striatum of each mouse using a total protein extraction kit (Merck Millipore) according to the manufacturer's protocol. Total protein extracts of equal amounts from each sample were subjected to western blot analysis with a mouse anti-α-Syn antibody (1:200, Abcam).

**α-Syn Drosophila melanogaster and driver lines for transgene expression.** The α-Syn transgenic fly, UAS-α-Syn (FBst0008146), was purchased from the Bloomington Drosophila stock center, and the transgenic hOmi Drosophila was created in this work. The driver line elav-GAL4 (FBst0000458) of
Drosophila melanogaster was used for pan-neuronal expression of transgenes, and the driver line GMR-GAL4 (FBst0009146) of Drosophila melanogaster was used to express transgenes in the eye. Flies were reared on standard cornmeal-sucrose-yeast-agar-molasses medium at 25 °C under a 12 h light/12 h dark cycle with 60% humidity. All fly work, unless otherwise stated, was performed at 25 °C to enhance GAL4 activity. We used the elav-GAL4 or GMR-GAL4 driver line as wild-type flies. Transgenic lines were crossed with the elav-GAL4 driver for protein expression in the brain or with the GMR-GAL4 driver for protein expression in the eye.

Generation of Drosophila melanogaster expressing hOmi pan-neuronally. The cDNA of human HtrA2/Omi (hOmi) was amplified by PCR from the cDNA clones (Invitrogen Thermo Fisher). The amplified PCR product was digested by flanking restriction enzyme sites and subcloned into the same restriction sites in the GAL4-responsive pUAST expression vector. The vector construct was co-injected into w1118 Drosophila melanogaster embryos with a plasmid bearing P element transposase under the control of the heat shock 70 (hs-α) promoter to drive the expression of transposase following standard microinjection methods (BestGene Inc.). Balanced activator lines were generated using standard genetic techniques at BestGene Inc. The generation of transgenic flies was confirmed by PCR using primers to detect the hOmi gene and western blot analysis using an anti-HtrA2/Omi antibody. The transgenic hOmi Drosophila line was heterozygous for the dominantly marked balancer chromosome carrying a dominant mutation, CyO, which causes curly wings.

PCR. The genotypes of the Drosophila lines were detected by PCR using EF Taq Polymerase (Solgent) following the manufacturer’s suggestion, in which 5 µL EF Taq buffer, 1 µL dNTPs, 0.5 µL forward primer (10 pmol/µL), and 0.5 µL reverse primer (10 pmol/µL) together with 50 ng genomic DNA in ddH2O water to 50 µL made up the PCR mix. Drosophila genomic DNA was isolated using DNAzol (Invitrogen). After the initial denaturation at 95 °C for 5 min, PCR was carried out by denaturation at 95 °C for 30 sec, annealing at 57 °C for genotyping α-Syn, 65 °C for genotyping hOmi for 45 sec and extension at 72 °C for 1 min. After completion of 34 cycles, a final extension of 10 min was applied. The PCR products were confirmed by agarose gel electrophoresis using loading star (Dyne Bio) and a 100-bp DNA ladder (Dyne Bio). α-Syn F primer: 5′-TGT AGG CTC CAC ACA GAC CGA GG-3′; R primer: 5′-GCT CCC TCG ACT GTG TCT TG-3′ and hOmi F primer: 5′-GTC GCC GGA TCC ATG CGT CAC ATT-3′; R primer: 5′-GAG CTC TCG AGT CAT TCT GTG ACC-3′.

Generation of Drosophila melanogaster co-expressing hOmi and α-Syn pan-neuronally. Female Drosophila model of PD (α-Syn Drosophila, FBst0008146) was mated with male hOmi Drosophila which maintains hOmi with CyO dominant mutation in balancer chromosome. In the F1 generation, the flies were sorted based on the dominant phenotypes of the CyO mutation and selected +/hOmi; α-Syn+/+ flies. The F1 generation, +/hOmi; α-Syn+/+ flies were crossed with each other to generate various genotypes. By genotyping the progenies born from a male fly and a female fly of the F2 generation, homozygous x/y; hOmi/hOmi; α-Syn/α-Syn Drosophila melanogaster were identified. The identified homozygous x/y; hOmi/hOmi; α-Syn/α-Syn Drosophila melanogaster were maintained by crossing them with each other. The homozygous hOmi/hOmi; α-Syn/α-Syn male Drosophila melanogaster was crossed with 3–4 female elav-GAL4 virgin Drosophila melanogaster to produce Drosophila melanogaster with pan-neuronal co-expression of hOmi and α-Syn. After 48 h of breeding, the flies were transferred to a fresh tube. The presence of the hOmi and α-Syn genes was observed in the progeny.

Pan-neuronal and eye-specific expression of transgenes in Drosophila. Pan-neuronal expression of transgenes was achieved by crossing virgin female flies (driver line) carrying elav-GAL4 on their X chromosome with male transgenic flies. Eye-specific expression of transgenes was achieved by crossing virgin female flies (driver line) carrying GMR-GAL4 on their X chromosome with male transgenic flies. These flies were maintained at 25 °C and, immediately after eclosion, sorted for western blotting, IHC, and survival and locomotion assays.

Locomotion assay. Fifteen flies of each group were anesthetized with CO2 and placed in a 15-mL conical tube (SPL life sciences) capped with cotton. Anesthetized flies were allowed to recover for 30 min at room temperature before the climbing assay. Flies were tapped to the bottom of the tube and allowed to climb with video recording for 30 sec. The experiments were repeated 3 times. After 10–15 sec, the numbers of flies remaining below the 2 mL mark (nbottom), and the flies the 10 mL mark (ntop) were recorded. The performance index (PI) was calculated for each group using the following formula: PI = 0.5 × (nbottom + ntop - nbottom/nbottom), where nbottom is the total number of flies, ntop is the total number of flies at the top, and nbottom is the total number of flies at the bottom. If all flies climb to the top of the tube, the score is 1, and if no flies climb the score is 0.42.

Survival assay. Newly eclosed flies of each group were allowed to mature for 48 h, and then the male and female flies were separated into different jars. Exactly 100 adult female and 100 adult male flies were maintained for the aging experiments. The flies of each group were maintained on standard cornmeal-sucrose-yeast-agar-molasses medium at 25 °C in a 60% humidified incubator (Han Baek Scientific Co.) with a 12-h light/dark cycle. During maintenance, the flies were transferred to fresh medium every day to avoid non age related death and their survival was recorded. This process was continued until all the flies had died. Analysis of the survival data was performed using the Kaplan–Meier method.41

Histological examinations of the brains of mice and Drosophila. Brains of four-week-old mnd2/mnd2 mice and age-matched control mice were removed and fixed by transcardial perfusion with ice-cold PBS followed by 4% paraformaldehyde in PBS. Subsequently, those were post-fixed in the same fixative for 4 h at 4 °C and incubated overnight at 4 °C in 30% sucrose in PBS. For the Drosophila experiment, fly heads were fixed in 10% neutral-buffered formalin. The fixed mouse brains and fly heads were embedded in paraﬃn and sliced into 4-μm-thick sections on a freezing microtome machine. The sections were deparaffinized with xylene,
rehydrated with a descending series of diluted ethanol and water, and permeabilized with 1% Triton X-100 in TBS for 30 min at RT. Antigens in the sections were retrieved with 10 mM sodium citrate buffer (pH 6.0) for 20 min at 85 °C and subsequently blocked with 10% normal goat serum (Sigma Aldrich) in TBS containing 1% BSA and 0.025% Triton X-100 at RT for 1 h. To observe the co-localization of α-Syn and hOmi in mouse brain, the sections were double-stained at 4 °C with a mouse anti-α-Syn antibody (1:200, Abcam) and a rabbit anti-HtrA2/Omi antibody (1:200, Abcam). For the Drosophila brain, however, the sections were double-stained at 4 °C with mouse anti-α-Syn antibody (ASy05) (1:400, Agricera antibodies) and a rabbit anti-HtrA2/Omi antibody (1:400, Abcam). The sections were sequentially washed 3 times for 10 min with TBST (TBS and 0.20% Tween-20), 2 times for 5 min with TBS-Triton X-100 (TBS and 0.025% Triton X-100) and one time for 10 min with TBST. To suppress endogenous peroxidase activity, the sections were incubated with 3% hydrogen peroxide (H$_2$O$_2$) in 40% methanol in TBS for 20 min. After washing, all the primary antibodies were detected by incubation with their corresponding secondary antibodies, Alexa Fluor 488-conjugated goat anti-mouse IgG (H + L) (1:400, Invitrogen) and Alexa Fluor 568-conjugated goat anti-rabbit IgG (H + L) (1:400, Invitrogen), at RT for 2 h in a dark humidified environment. The stock solutions of primary and secondary antibodies were diluted in antibody dilution buffer (2% goat serum, 1% BSA and 0.025% Triton X-100 in TBS). After washing 5 times for 10 min with TBST, the slides were sealed with aqueous mounting medium, and confocal images were obtained with a Carl Zeiss LSM510 Meta microscope. For immunoperoxidase staining, permeabilized slice sections, prepared as described above, were incubated in 10 mM sodium citrate buffer with boiling for 5 min. Endogenous peroxidase was blocked using an endogenous peroxidase blocking buffer (3% H$_2$O$_2$ and 40% methanol in TBS), followed by 10% horse serum (Sigma Aldrich) and 1% BSA with 0.025% Triton X-100. After washing, the sections were incubated with avidin and biotin (Vector Laboratories Inc.), followed by primary antibody at 4 °C for 16 h and secondary antibody for 2 h at room temperature. The antibody-treated slides were incubated with ABC reagents (Vector Laboratories Inc.) for 30 min at room temperature. Finally, they were stained with DAB substrate (Vector Laboratories Inc.). The tissue integrity of the Drosophila tissues was visualized after hematoxylin and eosin staining (H&E staining) which was performed according to a previously described method.

The Immunocytochemical confocal microscopic assay of mouse neurons. To observe the localization of α-Syn and HtrA2/Omi in mitochondria, primary neurons were isolated from the substantia nigra and striatum and cultured to 60% confluency using a standard primary cell culture method. After staining with Mito Tracker Red CMXRos (Invitrogen) according to the manufacturer’s instructions, the neurons were fixed with 4% paraformaldehyde in PBS for 20 min and permeabilized with 0.5% Triton X-100 in TBS for 30 min at room temperature. The neurons were then blocked for immunohistochemical analysis. After washing with TBST, the neurons were treated overnight at 4 °C with a rabbit anti-α-Syn antibody (1:100, Abcam) or a rabbit anti-HtrA2/Omi antibody (1:100, Abcam). After washing, the neurons were treated with FITC-conjugated goat anti-rabbit IgG (H + L) antibody (1:400, Abcam) for 2 h at room temperature. To detect the localization of α-Syn and HtrA2/Omi in ER, neurons fixed with 4% paraformaldehyde in PBS were permeabilized and blocked as described above. After washing with TBST, the neurons were double-stained overnight at 4 °C with a rabbit anti-α-Syn antibody (1:100, Abcam) or a rabbit anti-HtrA2/Omi antibody (1:100, Abcam) together with the ER marker mouse anti-PDI antibody (1:100, Abcam). After washing, the anti-α-Syn and anti-HtrA2/Omi antibodies were detected with secondary FITC-conjugated goat anti-rabbit IgG (H + L) antibody (1:400, Abcam), and the anti-PDI antibody was detected with Texas Red conjugated goat anti-mouse IgG (H + L) antibody (1:400, Abcam). The stock solutions of primary and secondary antibodies were diluted in antibody dilution buffer (2% goat serum, 1% BSA and 0.025% Triton X-100 in TBS). Confocal images were obtained with a Carl Zeiss LSM510 Meta microscope.

Preparation of Drosophila and mouse brain homogenates. Fly heads were homogenized using an ultrasonicator at 4 °C for 6 min at 40 kHz in 3 µL of total protein extraction kit TM buffer containing 0.1% SDS (Millipore). The homogenized lysates were centrifuged at 17,000 × g for 1 min at RT to remove the debris. The supernatant was collected and centrifuged again under the same conditions to collect the fresh supernatant. Four-week-old mnd2/mnd2 mice and aged match controls were sacrificed, and the brain tissues were homogenized by glass homogenizers. The supernatant was collected and centrifuged under the same conditions to collect the final homogenate. The homogenized lysates were centrifuged at 13,000 × g for 10 h. The supernatant was collected and centrifuged at 17,000 × g for 1 min at RT to remove the debris. The supernatant was collected and centrifuged again under the same conditions to collect the fresh supernatant. Four-week-old mnd2/mnd2 mice and aged match controls were sacrificed, and the brain tissues were homogenized by glass homogenizers. The supernatant was collected and centrifuged under the same conditions to collect the final homogenate.

Scanning electron microscopy study. Freshly sacrificed flies were dehydrated by serial transferring into increasing ethanol concentrations of 30, 40, 50, 60, 70, 80, 90, and 100% for 10 min at room temperature. The dehydrated flies were air dried prior to being preserved at −80 °C. The dehydrated flies were mounted on a slide with one eye upward on black tape using colloidal graphite in an isopropanol base. The flies were fixed in osmium tetroxide and air dried prior to observation. All flies were placed on a rotating platform to permit orientation under a vacuum and imaged at 180 × magnification using a JSM-6400 scanning electron microscope (JEOL Ltd.).

Statistical analysis. All statistical analyses are reported as the mean ± SEM, and the significance was calculated using one-way ANOVA followed by Bonferroni/Tukey multiple tests for individual means using IBM SPSS statistics 21 software. P values less than 0.05 were considered statistically significant. The intensity of oligomeric α-Syn was analyzed using Image-J software. When representative images are shown, at least three repeats were performed.

Data availability. The Data that support the findings of this study are available from the corresponding author upon reasonable request.
Yoshida, T., Mizuta, T. & Shimizu, S. Neurodegeneration in mnd2 mutant mice is not prevented by parkin transgene.

Yasuda, T., Nakata, Y., Choong, C. J. & Mochizuki, H. Neurodegenerative changes initiated by presynaptic dysfunction. Trans. Neurol. Gen. 2, 16 (2013).

Park, S. C. et al. Functional characterization of alpha-synuclein protein with antimicrobial activity. Biochem. Biophys. Res. Commun. 478, 924–928 (2016).

Luk, K. C. et al. Pathological alpha-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Non-transgenic Mice. Science 338, 949–953 (2012).

Taschenberger, G. et al. Aggregation of alpha-Synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 123, 671–683 (2012).

Cook, C. & Petrucelli, L. A critical evaluation of the ubiquitin–proteasome system in Parkinson’s disease. e. Biochem. Biophys. Acta 1792, 644–675 (2009).

Ebrahimi-Fakhari, D. et al. Distinct roles in vivo for the ubiquitin–proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J. Neurosci. 31, 14508–14520 (2011).

Pan, T., Kondo, S., Le, W. & Jankovic, J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain 131, 1969–1978 (2008).

Wang, C. & Wang, X. The interplay between autophagy and the ubiquitin-proteasome system in cardiac proteotoxicity. Biochem. Biophys. Acta 1852, 188–194 (2015).

Ingelsson, M. Alpha-Synuclein Oligomers–Neurotoxic Molecules in Parkinson’s Disease and Other Lewy Body Disorders. Front. Neurol. 10, 408 (2016).

Kokhan, V. S., Afanasieva, M. A. & Van’kin, G. I. alpha-Synuclein knockout mice have cognitive impairments. Behav. Brain Res. 231, 226–230 (2012).

Roostaei, A., Beaudoin, S., Staskevicius, A. & Roucou, X. Aggregation and neurotoxicity of recombinant alpha-synuclein aggregates initiated by dimerization. Mol. Neurodegener. 8, 5 (2013).

Wan, O. W. & Chung, K. K. K. The Role of Alpha-Synuclein Oligomerization and Aggregation in Cellular and Animal Models of Parkinson’s Disease. PLoS One 7, e38545 (2012).

Clausen, T., Southan, C. & Ehrmann, M. The HtrA Family of Proteases: Implications for Protein Composition and Cell Fate. Mol. Cell 10, 443–455 (2002).

Lipinska, B., Sharma, S. & Georgopoulos, C. Sequence analysis and regulation of the htrA gene of Escherichia coli: a sigma 32-independent mechanism of heat-inducible transcription. Nucleic Acids Res. 16, 10053–10067 (1988).

Liu, M. L. et al. Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-3. Journal of Cell Science 122, 1917–1926 (2009).

Martins, L. M. et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell Biol. 24, 9848–9862 (2004).

Strauss, K. M. et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum. Mol. Genet. 14, 2099–2111 (2005).

Abou-Seilman, P. M., Muqit, M. M. & Wood, N. W. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat. Rev. Neurosci. 7, 207–219 (2006).

Henchcliffe, C. & Beal, M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4, 600–609 (2008).

Breydo, L., Wu, J. W. & Uversky, V. N. alpha-Synuclein misfolding and Parkinson’s disease. Biochem. Biophys. Acta. 1822, 261–285 (2012).

Ryu, E. J. et al. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson’s disease. e. J. Neurosci. 22, 10690–10698 (2002).

Winkler, K. F. & Hahs, C. Mitochondrial dysfunction in Parkinson’s disease. Biochem. Biophys. Acta. 1802, 29–44 (2010).

Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson’s disease. J. Biol. Chem. 278, 31469–31472 (2003).

Todd, A. M. & Staveley, B. E. Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson’s disease. Genome 51, 1040–1046 (2008).

Bellani, S. et al. The regulation of synaptic function by alpha-synuclein. Commun. Integr. Biol. 3, 106–109 (2010).

Burrell, J. The Synaptic Function of alpha-Synuclein. J. Parkinsons Dis. 5, 699–713 (2015).

M’Angale, P. G. & Staveley, B. E. Effects of alpha-synuclein expression in the developing Drosophila eye. Dros. Inf. Serv. 95, 85–89 (2012).

Martins, L. M. et al. The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif. J. Biol. Chem. 277, 439–444 (2002).

Shi, Y. Mechanisms of Caspase Activation and Inhibition during Apoptosis. Mol. Cell. 9, 459–470 (2002).

Srinivasula, S. M. et al. Inhibitor of Apoptosis Proteins Are Substrates for the Mitochondrial Serine Protease Omi/HtrA2. J. Biol. Chem. 278, 31469–31472 (2003).

Crook, N. E., Clem, R. J. & Miller, L. K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 67, 2168–2174 (1993).

Jones, J. M. et al. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 425, 721 (2003).

Plun-Favreau, H. et al. The mitochondrial protease HtrA2 is regulated by Parkinson’s disease-associated kinase PINK. 1. Nat. Cell Biol. 9, 1243–1252 (2007).

Tain, L. S. et al. Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin. Cell Death Differ 16, 1118–1125 (2009).

Yoshida, T., Mizuta, T. & Shimizu, S. Neurodegeneration in mnd2 mutant mice is not prevented by parkin transgene. Biochem. Biophys. Res. Commun. 402, 676–679 (2010).

Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N. & Rubinsztein, D. C. alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009–25013 (2003).

Neumann, M. et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 1429–1439 (2002).

Ugalde, C. L., Finkelstein, D. L., Lawson, V. A. & Hill, A. F. Pathogenic mechanisms of prion protein, amyloid-3 and alpha-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. J. Neurochem. 139, 162–180 (2016).

Cassone, M., Gagne, A. L., Spruce, L. A., Seeholzer, S. H. & Sebert, M. E. The HtrA Protease from Streplococcus pneumoniae Digests Both Denatured Proteins and the Competence-stimulating Peptide. J. Biol. Chem. 287, 38449–38459 (2012).

White, K. E., Humphrey, D. M. & Hirth, F. The dopaminergic system in the aging brain of drosophila. Front Neurosci. 4, 205 (2010).
43. Chung, H. J., Sharma, S. P., Kim, H. J., Baek, S. H. & Hong, S. T. The resveratrol-enriched rice DJ526 boosts motor coordination and physical strength. *Sci. Rep.* **6**, 23958 (2016).

44. Hawrot, E. & Patterson, P. H. Long term culture of dissociated sympathetic neurons. *Methods Enzymol.* **58**, 574–584 (1979).

**Acknowledgements**

This research was supported by the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2017M3C7A1044818). We appreciate Jinny Hong, Department of Biochemistry, Case Western Reserve University for reviewing the manuscript.

**Author contributions**

H.J.C. and M.A.M.J. designed the project; H.J.C. and M.A.M.J. designed the experiments; H.J.C. and M.A.M.J. analyzed results; H.J.C. and M.A.M.J. performed the experimental work; and H.J.C., M.A.M.J. and S.T.H. wrote the manuscript. H.J.C. and S.T.H. revised the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-62309-z.

**Correspondence** and requests for materials should be addressed to S.-T.H.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020